Top 10 Lemborexant (Dayvigo) Generic Manufacturers in Brazil
The Brazilian pharmaceutical market is one of the largest in Latin America, with a projected value of approximately $41 billion by 2024, growing at a compound annual growth rate (CAGR) of 6.3%. The demand for generic medications, including Lemborexant (Dayvigo), has surged due to increasing healthcare costs and a growing emphasis on affordable treatment options. In 2022, generics accounted for over 40% of the total drug sales in Brazil, reflecting the significant shift towards cost-effective pharmaceutical solutions. This report outlines the top ten manufacturers of Lemborexant generics in Brazil, detailing their market performance and contributions to the sector.
1. Eurofarma
Eurofarma is a leading Brazilian pharmaceutical company with a robust portfolio of generic medications, including Lemborexant. In 2022, Eurofarma reported revenues exceeding $1 billion and holds a 7% market share in the Brazilian generic market. Their commitment to innovation and quality ensures a significant presence in the Lemborexant segment.
2. Aché Laboratórios
Aché Laboratórios is among Brazil’s top pharmaceutical companies, with an extensive range of therapeutic areas. The company has a 5% share in the generics market and reported sales of around $800 million in 2022. Aché’s strategic partnerships and investment in R&D enhance its ability to offer competitive Lemborexant generics.
3. Biolab Sanus Farmacêutica
Biolab Sanus is known for its focus on high-quality generics. In 2022, the company captured approximately 4% of the generics market in Brazil, with sales around $600 million. Their manufacturing capabilities and commitment to research ensure that their Lemborexant products meet high standards.
4. EMS S/A
EMS is a major player in Brazil’s pharmaceutical industry, holding a strong position in the generics market with a 10% share. The company achieved sales of $1.2 billion in 2022, largely due to its extensive distribution network and strong brand recognition. EMS offers a competitive line of Lemborexant generics.
5. Sanofi Brazil
Sanofi, a global healthcare leader, operates a significant branch in Brazil, contributing to the generic market. The company’s generics division reported approximately $500 million in sales in 2022, with a focus on accessibility and affordability in medications like Lemborexant.
6. Prati-Donaduzzi
Prati-Donaduzzi is a well-established Brazilian pharmaceutical manufacturer specializing in generics. The company holds about 3% of the market share and had revenues of approximately $400 million in 2022. Their production facilities are equipped for high-quality Lemborexant generics.
7. Laboratório Teuto Brasileiro
Teuto is a prominent player in Brazil’s generic market with a focus on affordability and quality. With a market share of around 3%, the company reported revenues of about $350 million in 2022. Teuto’s offerings in Lemborexant are well-positioned to meet growing demand.
8. União QuÃmica
União QuÃmica is recognized for its commitment to providing high-quality generics. The company has a 2% share in the Brazilian generic market, generating roughly $300 million in sales in 2022. Their focus on innovation positions them favorably in the Lemborexant segment.
9. Laboratório Sanfar
Sanfar is an emerging pharmaceutical manufacturer in Brazil, focusing on generics. The company reported sales of about $250 million in 2022, with a market share of 1.5%. Their Lemborexant generics are gaining traction among healthcare providers.
10. Galena Indústria Farmacêutica
Galena operates as a mid-sized player in Brazil’s generics market, with a focus on niche therapeutic areas. The company achieved revenues of approximately $200 million in 2022 and holds a 1% market share. Their entry into Lemborexant generics reflects a strategic expansion effort.
Insights and Future Trends
The Brazilian market for Lemborexant generics is poised for growth, driven by increasing demand for affordable healthcare solutions. By 2025, the generic drug market in Brazil is expected to reach approximately $18 billion, with Lemborexant showing significant potential for expansion. As more manufacturers enter the market and invest in R&D, competition will intensify, leading to improved accessibility and lower prices for consumers. Additionally, the Brazilian government’s initiatives to promote generic medications are likely to further boost market growth, positioning Brazil as a key player in the global pharmaceutical landscape.
Related Analysis: View Previous Industry Report
